skip to primary navigationskip to content
 

Taking parked therapies into overdrive

last modified Apr 28, 2014 04:09 PM
Healx3 is aiming to breathe new life into parked therapeutics and dormant IP in the biopharmaceutical industry.

 

The start-up, based at ideaSpace West, hopes to take the medical technology parked by biopharmaceutical companies and turn it into new drugs and therapies. Healx3 is currently in talks with biopharma companies on potential partnerships.

In an interview with Business Weekly, CEO Tim Guilliams, who holds a PhD in molecular neuroscience from the University of Cambridge, says: “Around 90 per cent of drug development projects never make it to market – leaving a vast amount of parked bio-assets on company benches.

“Some of these assets still have therapeutic potential, but do not cure patients or generate revenue. Healx3 is specialising in the upcycle and out-licensing of parked therapeutics and dormant IP in the biopharmaceutical industry.

“By enabling companies to generate new revenue streams and promote collaborative innovation within the industry, our activities will help deliver the next generation of therapeutics to patients in need.”

Healx3 is currently self-funded but aims to seek angel support once it has created strategic partnerships, launching a pilot with around 10 assets and pushing for seed capital around September.

To read the full article visit here

For more on Healx3 see http://www.healx3.com/

RSS Feed Latest news

The writing's on the wall: Blackboard win WOW Award

Sep 18, 2017

Ally recognised for impact on student success

Your liver on a microchip - a revolution in drug development

Aug 17, 2017

Funding for a cutting edge alternative to animal testing

An interview with Steve Marsh from GeoSpock

Aug 17, 2017

Steve talks extreme data and building the tech of the future

Shining a light on Polysolar

Aug 14, 2017

Generating power through sustainable energy sourcing

Sparrho spreads its wings

Jul 17, 2017

Sparrho raises $3 million to democratize access to science research

View all news